Effect of blueberry on type 2 Diabetic Nephropathy

The effect of hydroalcoholic capsular extract of Blueberry on nephropathic complications of diabetes mellitus type 2

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015040712438N12

Enrollment

Registered

2015-05-26

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy. Non-insulin-dependent diabetes mellitus with renal complications

Interventions

Intervention 1: intervention group:routine treatment+blueberry cap BID,3 months. Intervention 2: control group:routine treatment+placebo cap BID,3 months.

Treatment - Drugs

Placebo

intervention group:routine treatment+blueberry cap BID,3 months

control group:routine treatment+placebo cap BID,3 months

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: patients 35 to 70 years old receiving reducer blood glucose drug and dietary recommendations for 3 to 5 years with type II diabetes. That HbA1c is 9-7%. LDL-cholesterol less than 130 and triglycerides less than 300. with 0 and 1Stage of diabetic nephropathy that do not use fat-lowering drugs. Exclusion criteria: liver disease, allergies to plants used in the clinical trial, changing the dose of drug during the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HbA1C. Timepoint: Baseline and End-of-trial. Method of measurement: percent of glycosylated hemoglobin.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;Lipid profile. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;TAC. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;ALT,AST. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;BUN. Timepoint: Baseline and End-of-trial. Method of measurement: urine sample.;Creatinin. Timepoint: Baseline and End-of-trial. Method of measurement: urine sample.;PRO. Timepoint: Baseline and End-of-trial. Method of measurement: urine sample.	—

Measure

Time frame

HbA1C. Timepoint: Baseline and End-of-trial. Method of measurement: percent of glycosylated hemoglobin.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;Lipid profile. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;TAC. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;ALT,AST. Timepoint: Baseline and End-of-trial. Method of measurement: blood sample.;BUN. Timepoint: Baseline and End-of-trial. Method of measurement: urine sample.;Creatinin. Timepoint: Baseline and End-of-trial. Method of measurement: urine sample.;PRO. Timepoint: Baseline and End-of-trial. Method of measurement: urine sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.M.Taghizadeh

Kashan University of Medical Sciences

taghizadeh_m@kaums.ac.ir+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026